BioCentury | Mar 13, 2020
Product Development

March 12 Quick Takes: WuXi AppTec’s Wuhan site back online; plus SOX relief, AZ, BMS, Nicox-Ocumesion, Tyligand-Context

All WuXi AppTec Chinese sites operating  WuXi AppTec Co. Ltd. (Shanghai:603259; HKEX:2359) said it has resumed operations at its Wuhan facility, which provides discovery chemistry services. The company has now restarted operations at all its...
BioCentury | Jan 9, 2018
Finance

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Nov 3, 2017
Company News

Nicox, Re-Vana partner for sustained-release formulations for IOP

Nicox S.A. (Euronext:COX) and Re-Vana Therapeutics Ltd. (Belfast, U.K.) partnered to develop Re-Vana's EyeLief drug delivery platform for sustained release of Nicox's stand-alone nitric oxide (NO)-donors to reduce intraocular pressure (IOP). Under the non-exclusive agreement,...
BC Week In Review | Aug 18, 2017
Clinical News

Valeant expects to resolve manufacturing issues after second Vyzulta CRL

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said that the CGMP inspection issues identified at its Bausch + Lomb manufacturing facility in Tampa, Fla., will soon be “satisfactorily resolved.” Earlier this month, Valeant received a second...
BC Week In Review | Aug 11, 2017
Clinical News

Valeant gets second CRL for Vyzulta

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said FDA issued a second complete response letter for Vyzulta latanoprostene bunod to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Valeant said the CRL...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
BioCentury | Jul 7, 2017
Finance

Onward and upward

The top three market cap tiers continued to outperform smaller caps in 2Q17, led by companies valued between $1 billion and $9.9 billion. Companies valued below $1 billion failed to carry over their momentum from...
BC Week In Review | Jun 2, 2017
Clinical News

FDA approves Nicox’s Zerviate for ocular itching

Nicox S.A. (Euronext:COX) said FDA approved an NDA for Zerviate cetirizine (AC-170) to treat ocular itching associated with allergic conjunctivitis. The approval is Nicox's first in the U.S. Last October, FDA issued a complete response...
BC Extra | May 31, 2017
Company News

Nicox’s Zerviate wins FDA nod for ocular itching

Nicox S.A. (Euronext:COX) jumped €2.26 (21%) to €12.85 Wednesday after FDA approved an NDA for Zerviate cetirizine to treat ocular itching associated with allergic conjunctivitis. The approval is Nicox's first in the U.S. In October...
Items per page:
1 - 10 of 529
BioCentury | Mar 13, 2020
Product Development

March 12 Quick Takes: WuXi AppTec’s Wuhan site back online; plus SOX relief, AZ, BMS, Nicox-Ocumesion, Tyligand-Context

All WuXi AppTec Chinese sites operating  WuXi AppTec Co. Ltd. (Shanghai:603259; HKEX:2359) said it has resumed operations at its Wuhan facility, which provides discovery chemistry services. The company has now restarted operations at all its...
BioCentury | Jan 9, 2018
Finance

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Nov 3, 2017
Company News

Nicox, Re-Vana partner for sustained-release formulations for IOP

Nicox S.A. (Euronext:COX) and Re-Vana Therapeutics Ltd. (Belfast, U.K.) partnered to develop Re-Vana's EyeLief drug delivery platform for sustained release of Nicox's stand-alone nitric oxide (NO)-donors to reduce intraocular pressure (IOP). Under the non-exclusive agreement,...
BC Week In Review | Aug 18, 2017
Clinical News

Valeant expects to resolve manufacturing issues after second Vyzulta CRL

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said that the CGMP inspection issues identified at its Bausch + Lomb manufacturing facility in Tampa, Fla., will soon be “satisfactorily resolved.” Earlier this month, Valeant received a second...
BC Week In Review | Aug 11, 2017
Clinical News

Valeant gets second CRL for Vyzulta

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said FDA issued a second complete response letter for Vyzulta latanoprostene bunod to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Valeant said the CRL...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
BioCentury | Jul 7, 2017
Finance

Onward and upward

The top three market cap tiers continued to outperform smaller caps in 2Q17, led by companies valued between $1 billion and $9.9 billion. Companies valued below $1 billion failed to carry over their momentum from...
BC Week In Review | Jun 2, 2017
Clinical News

FDA approves Nicox’s Zerviate for ocular itching

Nicox S.A. (Euronext:COX) said FDA approved an NDA for Zerviate cetirizine (AC-170) to treat ocular itching associated with allergic conjunctivitis. The approval is Nicox's first in the U.S. Last October, FDA issued a complete response...
BC Extra | May 31, 2017
Company News

Nicox’s Zerviate wins FDA nod for ocular itching

Nicox S.A. (Euronext:COX) jumped €2.26 (21%) to €12.85 Wednesday after FDA approved an NDA for Zerviate cetirizine to treat ocular itching associated with allergic conjunctivitis. The approval is Nicox's first in the U.S. In October...
Items per page:
1 - 10 of 529